Edgewise Therapeutics
Hector Rodriguez has extensive work experience in the field of biology and biochemistry. Hector started their career as a Graduate Student at the University of California, Santa Cruz in 1995 and completed their studies in 2001. After that, they joined Cytokinetics, Inc. as a Scientist III, specializing in biochemistry and managing the protein production group. Hector worked there until 2007 and was responsible for developing biochemical assays for various purposes.
In 2007, Hector became the Head of Analytical Biochemistry at Arresto BioSciences, where they established and managed the Analytical Biochemistry group. Hector conducted immunizations, screened hybridoma libraries, and developed biochemical assays for lead candidate screening.
Hector then joined Calithera Biosciences in 2010 as the Associate Director of Biochemistry. Hector established the Biochemistry group, developed biochemical assays for screening, and was responsible for expression and purification of enzyme targets.
In 2012, Hector joined MyoKardia as the Senior Director of Biology. Hector held this position until 2017 and was responsible for leading the biology team. During their time at MyoKardia, they contributed to the development of cardiovascular therapeutics.
In 2017, Hector joined Edgewise Therapeutics as a Scientific Consultant. Hector provided scientific consultancy services until an unspecified date.
Currently, Hector is employed at BridgeBio, where they work in the field of biology. The exact role and duration of their employment at BridgeBio are not specified.
Hector Rodriguez's education history includes attending Modesto Junior College from 1990 to 1992, where they studied chemistry. Hector then transferred to the University of California, Davis, from 1993 to 1994, and obtained a Bachelor of Science degree in Biochemistry. Continuing their academic journey, they pursued a Ph.D. in Chemistry at the University of California, Santa Cruz, from 1995 to 2001.
This person is not in any offices
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.